Psychiatry;Psychiatrie

Revue Medicale Suisse

Volumn 1, Issue 2, 2005, Pages 159-167

  Bryois, Christian ^a   Nanzer, Nathalie ^b   Eliez, Stephan ^b   Etter, Manuela ^b   Aubry, Jean Michel ^b   Bertschy, Gilles ^b  

^a Hôpital de Prangins   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BUSPIRONE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LAMOTRIGINE; LEVOMEPROMAZINE; LORAZEPAM; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROMAZINE; QUETIAPINE; RISPERIDONE; RITALINE LA; RITALINE SR; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; TRIAZINE DERIVATIVE;

ATTENTION DEFICIT DISORDER; BIPOLAR DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; REVIEW; MENTAL DISEASE;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; HUMANS; MENTAL DISORDERS; METHYLPHENIDATE; PIPERAZINES; QUINOLONES; RISPERIDONE; TRIAZINES;

EID: 21844463100     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-9.
2. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics. part I, «Goldilocks» actions at dopamine receptors. J Clin Psychiatry 2001:62:841-2.
3. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: Illustrating their mechanism of action. J Clin Psychiatry 2001; 62: 923-4.
4. Rao ML, Moller HJ. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review. Neuropsychobiology 1994:30:160-72.
5. Richelson E. Receptor pharmacology of neuroteptics: Relation to clinical effects. J Clin Psychiatry 1999; 60(Suppl. 10): 5-14.
6. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerabillty, and safety of aripiprazole following single and multiple oral dose administration. Eur Neuropsychopharmacol 2000; 10 (Suppl. 3): 306-7.
7. Lieberman J, Carson WH, Saha AR, et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia (poster). Int J Neuropsychopharmacol 2002; 5 (Suppl. 1): S186.
8. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-71.
9. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-90.
10. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651-8.
11. Kasper S, Lermen MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003:6:325-37.
12. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048-56.
13. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents A multicenter randomized study. Psychopharmacology (Berl) 2003; 166: 391-9.
14. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61: 123-36.
15. Wolraich ML, Doffing MA. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 2004; 18: 243-50.
16. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: Proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003:60:204-11.
17. Lopez F, Silva R, Pestreich L et al. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyper-activity disorder across the school day. Paediatr Drugs 2003; 5: 545-55.
18. Markowicz JS, Straughn AB, Patrick KS, et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet 2003; 42: 393-401.
19. Wolraich MU Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 2001; 108: 883-92.
20. Oehl M, Hummer M, Reischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand 2000; 407 (Suppl.): 83-6.
21. Dolder CR, Lacro JR Dunn LB, et al. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103-8.
22. Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994; 10: 464-79.
23. Bloch Y, Mendlovic S, Strupinsky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: Do they hurt? J Clin Psychiatry 2001; 62: 855-9.
24. Ananth J, Burgoyne KS, Gadasalli R, et al. How do the atypical antipsychotics work? J Psychiatry Neurosci 2001; 26: 385-94.
25. Harrison TS, Goa KL. Long-acting risperidone: A review of its use in schizophrenia. CNS Drugs 2004; 18: 113-32.
26. Kane JM, Eerdekens M, Undenmayer JP, et al. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125-32.
27. Chue P, Eerdekens M, Augustyns I, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Schrzophr Res 2002; 53 (Suppl. 3): 174-5.
28. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64: 1250-7.
29. Hosalli P. Depot risperidone for schizophrenia (Cochrane Review). In: The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, 2004.
30. Compendium Suisse des Médicaments. Basel: Documed SA, 2004.
31. Fulton B, Goa KL. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997; 53: 281-98.
32. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149-51.
33. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59: 441-8.
34. Olanzapine for injection: New formulation. No advantage in agitated patients. Prescrire Int 2004; 13: 92-3.
35. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21: 389-97.
36. Lindborg SR, Beasley CM, Alaka K, et al. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res 2003; 119: 113-23.
37. Aubry JM, Ferrero F, Schaad N. Pharmacothérapie des troubles bipolaires. Genève: Médecine & Hygiène, 2004.
38. Aubry JM, Bertschy G, Bryois C, et al. Acquisitions thérapeutiques 2001. Psychiatrie. Med Hyg 2001; 59: 129-34.
39. Corn T, Ascher J, Calabrese JR. Lamotrigine in the treatment of bipolar (abstract). Presented at the American College of Neuropharmacology Annual Meeting: San Juan, Puerto Rico, 1996.
40. Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997; 72: 145-8.
41. Hoopes S, Snow M. Clinical effectiveness of lamotrigine with affective disorders (abstract). Presented at the Second International Conference on Bipolar Disorder: Pittsburgh, PA, 1997.
42. Calabrese JR, Bowden CL, Sachs GS, et al.A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79-88.
43. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-14.
44. Goldsmith DR, Wagstaff AJ, Ibbotson T, et al. Lamotrigine: A review of its use in bipolar disorder. Drugs 2003; 63: 2029-50.
45. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-24.
46. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.